Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-03-2019 | Cough | Original Article – Clinical Oncology

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

Authors: Sanna Iivanainen, Tuomo Alanko, Katriina Peltola, Teemu Konkola, Jussi Ekström, Henri Virtanen, Jussi P. Koivunen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2019

Abstract

Purpose

Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival of cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which is designed for follow-up of cancer patients receiving immune checkpoint inhibitors (ICI). Purpose of the current study is to investigate whether symptoms collected by Kaiku Health ePRO tool on cancer patients receiving immune checkpoint inhibitors (ICI) follows to symptoms reported in clinical trials and whether coupling of specific symptoms does occur.

Methods

We retrospectively collected data on symptom timing and severity, and QoL of patients followed with Kaiku Health IO module in two Finnish cancer centers between 2017 and 2018. Kaiku Health IO module consists of 18 adaptive questions, which assess the presence and severity of symptoms. Patients were requested (via e-mail) to fill online symptom questionnaires with 3–7 day interval and QoL questionnaires (QLQ-C30) with 1–2 month interval.

Results

The IO module was used to follow 37 patients who had filled in total 559 symptom questionnaires. There was good adherence to ePRO follow-up with a median of 11 questionnaires filled per patient. The reported symptoms and their severity follow closely what has been seen in clinical trials investigating ICIs. Correlation analysis of the symptoms showed the strongest positive correlations between itching and rash; nausea and vomiting, decreased appetite, or stomach pain; cough and shortness of breath.

Conclusions

The results of the current study suggest that real-world symptom data collected through the ePRO application on cancer patients receiving ICI therapy aligns with the data from clinical trials. Correlations between different symptoms occur, which might reflect therapeutic efficiency, side effects, or tumor progression. These correlations should be further investigated with data coupled to clinical outcomes.

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632. https://doi.org/10.1093/jnci/djp386 CrossRefPubMedPubMedCentral

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. https://doi.org/10.1200/JCO.2015.63.0830 CrossRefPubMed

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C et al (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198. https://doi.org/10.1001/jama.2017.7156 CrossRefPubMedPubMedCentral

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683 CrossRefPubMedPubMedCentral

Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62(5):337–347. https://doi.org/10.3322/caac.21150 CrossRefPubMed

Benze G, Nauck F, Alt-Epping B, Gianni G, Bauknecht T, Ettl J, Munte A, Kretzschmar L, Gaertner J (2017) PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer. Ann Palliat Med. https://doi.org/10.21037/apm.2017.07.05 CrossRefPubMed

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643 CrossRefPubMedPubMedCentral

Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2017) Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 18(12):1600–1609CrossRefPubMed

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574. https://doi.org/10.1093/annonc/mdv623 CrossRefPubMed

Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD et al (2011) Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 29(8):994–1000. https://doi.org/10.1200/JCO.2010.29.8315 CrossRefPubMedPubMedCentral

Denis F, Yossi S, Septans AL, Charron A, Voog E, Dupuis O et al (2017a) Improving survival in patients treated for a lung cancer using self-evaluated symptoms reported through a web application. Am J Clin Oncol 40(5):464–469. https://doi.org/10.1097/COC.0000000000000189 CrossRefPubMed

Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J et al (2017b) Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9):https://doi.org/10.1093/jnci/djx029

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME et al (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD anderson cancer center experience. Investig New Drugs 36(4):638–646. https://doi.org/10.1007/s10637-017-0534-0 CrossRef

Gilbert JE, Howell D, King S, Sawka C, Hughes E, Angus H et al (2012) Quality improvement in cancer symptom assessment and control: the provincial palliative care integration project (PPCIP). J Pain Symptom Manag 43(4):663–678. https://doi.org/10.1016/j.jpainsymman.2011.04.028 CrossRef

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J et al (2018) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdy162 CrossRefPubMedPubMedCentral

Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D (2008) Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer 16(7):791–801. https://doi.org/10.1007/s00520-007-0380-2 CrossRefPubMed

Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 CrossRefPubMed

Holch P, Warrington L, Bamforth LCA, Keding A, Ziegler LE, Absolom K et al (2017) Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment. Ann Oncol 28(9):2305–2311. https://doi.org/10.1093/annonc/mdx317 CrossRefPubMedPubMedCentral

Jensen RE, Snyder CF, Abernethy AP, Basch E, Potosky AL, Roberts AC et al (2014) Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract 10(4):e215–e222. https://doi.org/10.1200/JOP.2013.001067 CrossRefPubMed

Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32(14):1480–1501. https://doi.org/10.1200/JCO.2013.53.5948 CrossRefPubMed

Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, Klepstad P (2010) Health care providers underestimate symptom intensities of cancer patients: a multicenter european study. Health Qual Life Outcomes 8:104–7525. https://doi.org/10.1186/1477-7525-8-104 CrossRefPubMedPubMedCentral

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44CrossRefPubMed

Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL et al (2017) Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol 10(1):64-017. https://doi.org/10.1186/s13045-017-0433-z CrossRef

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33(18):2013–2020. https://doi.org/10.1200/JCO.2014.58.1041 CrossRefPubMedPubMedCentral

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148CrossRefPubMed

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentral

Mullen KH, Berry DL, Zierler BK (2004) Computerized symptom and quality-of-life assessment for patients with cancer part II: acceptability and usability. Oncol Nurs Forum 31(5):E84–E89. https://doi.org/10.1188/04.ONF.E84-E89 CrossRefPubMed

Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL (2008) Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 14(8):530–539PubMedPubMedCentral

Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP et al (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124(2):271–277. https://doi.org/10.1002/cncr.31043 CrossRefPubMed

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95-017. https://doi.org/10.1186/s40425-017-0300-z CrossRef

Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed

Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC et al (2013) A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer 21(6):1525–1550. https://doi.org/10.1007/s00520-012-1688-0 CrossRefPubMedPubMedCentral

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255–265CrossRefPubMed

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015a) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093 CrossRefPubMed

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015b) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082 CrossRefPubMed

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862CrossRefPubMed

Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001 CrossRefPubMed

Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A (2017) Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 69(4):687–699. https://doi.org/10.1002/art.40043 CrossRefPubMed

Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC (2012) Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 84(1):130–148. https://doi.org/10.1016/j.critrevonc.2012.02.011 CrossRefPubMed

Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY et al (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17(2):179–193. https://doi.org/10.1007/s11136-007-9295-0 CrossRefPubMed

Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM et al (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4):714–724. https://doi.org/10.1200/JCO.2004.06.078 CrossRefPubMed

Velikova G, Awad N, Coles-Gale R, Wright EP, Brown JM, Selby PJ (2008) The clinical value of quality of life assessment in oncology practice—a qualitative study of patient and physician views. Psychooncology 17(7):690–698. https://doi.org/10.1002/pon.1295 CrossRefPubMed

Velikova G, Keding A, Harley C, Cocks K, Booth L, Smith AB et al (2010) Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer 46(13):2381–2388. https://doi.org/10.1016/j.ejca.2010.04.030 CrossRefPubMed

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.3923 CrossRefPubMedPubMedCentral

Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785–792. https://doi.org/10.1200/JCO.2015.66.1389 CrossRefPubMed

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356. https://doi.org/10.1056/NEJMoa1709684 CrossRefPubMedPubMedCentral

Title: ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study
Authors: Sanna Iivanainen
Tuomo Alanko
Katriina Peltola
Teemu Konkola
Jussi Ekström
Henri Virtanen
Jussi P. Koivunen
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Keywords: Cough
Cough
Cough
Checkpoint Inhibitors
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-02835-6

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

ZWINT is the next potential target for lung cancer therapy

Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment

Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population